Sign in
Not yet recruitingPhase 3

Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)

Key facts

Who runs it
Institut Gustave Roussy
Where
France16 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
984 people, planned
Started
1 Mar 2026
Expected to end
1 Sept 2030
Type of study
Interventional
Record updated
28 January 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Women, men, transgender,18 ≤age ≤55
  • ECOG performance status ≤ 1
  • Patients infected with HIV are eligible for the study provided they are receiving antiretroviral therapy with undetectable viral load
  • Biopsy-proven HPV related HSIL at any site (vulvar VIN, vaginal VaIN, cervical CIN, anal AIN, penile) at baseline
  • Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the administration of the first vaccine injection
  • Sexually active patients must agree to use acceptable and appropriate contraception while included in BIO-HPV study and until the last dose of vaccine
  • Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol
  • Patients must be affiliated to a social security system or beneficiary of the same
  • Life expectancy of greater than 5 years

Who cannot take part

  • History of prior treatment of HSIL at the same site then currently treated
  • Prior HPV vaccination
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 21 days prior to the first dose of trial treatment
  • Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment
  • History of HPV related cancer (i.e. anal, genital, head and neck)
  • Prior malignancy active within the previous 3 years except from cancers with an expected PFS at 5 years of >95%
  • Hypersensitivity to the active substances or to any of the excipients (Listed in the SmPC)
  • Acute or severe febrile illness. Vaccination must be postponed until the individual has fully recovered
  • Pregnant women or intent to become pregnant
  • Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
  • Warts so extensive that they preclude the clinician from determining the extent and location of HSIL

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the efficacy of Human papilloma virus (HPV) vaccination as secondary prevention in patients with gynecological or anal HSIL.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2024-520140-42-00, who can take part
Record updated
28 January 2026